Heron Therapeutics (HRTX) Invested Capital (2016 - 2025)
Historic Invested Capital for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to $14.9 million.
- Heron Therapeutics' Invested Capital rose 13720.78% to $14.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.9 million, marking a year-over-year increase of 13720.78%. This contributed to the annual value of -$33.7 million for FY2024, which is 94.78% up from last year.
- According to the latest figures from Q3 2025, Heron Therapeutics' Invested Capital is $14.9 million, which was up 13720.78% from -$27.3 million recorded in Q2 2025.
- In the past 5 years, Heron Therapeutics' Invested Capital ranged from a high of $196.2 million in Q1 2021 and a low of -$40.0 million during Q3 2024
- Moreover, its 5-year median value for Invested Capital was -$21.7 million (2022), whereas its average is $15.4 million.
- Its Invested Capital has fluctuated over the past 5 years, first plummeted by 35031.68% in 2023, then surged by 13720.78% in 2025.
- Heron Therapeutics' Invested Capital (Quarter) stood at $77.6 million in 2021, then crashed by 82.5% to $13.6 million in 2022, then tumbled by 350.32% to -$34.0 million in 2023, then grew by 0.95% to -$33.7 million in 2024, then skyrocketed by 144.23% to $14.9 million in 2025.
- Its Invested Capital stands at $14.9 million for Q3 2025, versus -$27.3 million for Q2 2025 and -$28.5 million for Q1 2025.